Orpheus Medica is a privately held Canadian biopharmaceutical company leading innovation in discovery, research and development of natural and novel cannabinoid therapeutic agents for pain management and inflammatory conditions through our proprietary drug development platform. Orpheus’ proprietary drug candidates are screened, selected and optimized against validated molecular targets of interest with preferred bioavailability properties while minimizing off-target interactions and potential toxicity. The objective of Orpheus’ pain management program is to develop a potent, non-psychotropic, local or systemic analgesic for intractable pain that will be safe and well tolerated.